Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2005

Lack of effect of hyperoxia on photodynamic therapy and lipid peroxidation in three different cancer cell lines

Astrid Hjelde, Odrun A. Gederaas, Hans E. Krokan, Alf O. Brubakk

Med Sci Monit 2005; 11(10): BR351-356 :: ID: 430288

Abstract

Background:The use of photodynamic therapy (PDT) to treat malignant tumors involves a photosensitizing drug, light, and oxygen. Since PDT requires oxygen, the purpose of this study was to investigate whether increased oxygen tension increases cell death compared with normoxic conditions (21 kPa oxygen).Material/Methods:The effect of hyperoxia on PDT and lipid peroxidation was investigated in two human colon carcinoma cell lines, SW480 and WiDr, and one rat bladder cell carcinoma, AY-27. The cells were incubated with 2 mM 5-aminolaevulinic acid (5-ALA) for 3.5 h at 37°C. This treatment induces the accumulation of protoporphyrin IX (PpIX), which is a potent photosensitizer. PpIX absorbs light energy and produces singlet oxygen in the presence of molecular oxygen, which then destroys the cancer cells. The cells were illuminated (0.5–30 min) at room temperature by blue light (435 nm) prior to hyperoxia exposure. This treatment was performed in a small, temperature-controlled (37°C) hyperbaric chamber using oxygen at a pressure of 100, 200, 300, or 400 kPa.Results:PDT performed under normoxia induced lipid peroxidation and caused a considerable decrease in cell survival. However, this decrease was not influenced by the presence of hyperoxia (P>0.05). Furthermore, hyperoxic exposure (400 kPa O[sub]2[/sub]) alone caused no increase in lipid peroxidation compared with untreated control cells.

Keywords: Aminolevulinic Acid - administration & dosage, Colonic Neoplasms - pathology, Hyperoxia - metabolism, Lipid Peroxidation, Photochemotherapy, Photosensitizing Agents - administration & dosage, Protoporphyrins - administration & dosage, Urinary Bladder Neoplasms - pathology

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750